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Abstract: The classical ketogenic diet (cKD) is an isocaloric, high fat, very low-carbohydrate diet that
induces ketosis, strongly influencing leptin and ghrelin regulation. However, not enough is known
about the impact of a long-term cKD. This study evaluated the effects of a 12-month cKD on ghrelin
and leptin concentrations in children, adolescents and adults affected by the GLUT1-Deficiency
Syndrome or drug resistant epilepsy (DRE). We also investigated the relationship between the
nutritional status, body composition and ghrelin and leptin variations. We carried out a longitudinal
study on 30 patients: Twenty-five children and adolescents (15 females, 8 ± 4 years), and five adults
(two females, 34 ± 16 years). After 12-monoths cKD, there were no significant changes in ghrelin and
leptin, or in the nutritional status, body fat, glucose and lipid profiles. However, a slight height z-score
reduction (from −0.603 ± 1.178 to −0.953 ± 1.354, p ≤ 0.001) and a drop in fasting insulin occurred. We
found no correlations between ghrelin changes and nutritional status and body composition, whereas
leptin changes correlated positively with variations in the weight z-score and body fat (ρ = 0.4534,
p = 0.0341; ρ = 0.5901, p = 0.0135; respectively). These results suggest that a long-term cKD does not
change ghrelin and leptin concentrations independently of age and neurological condition.
Keywords: drug-resistant epilepsy; GLUT1-Deficiency Syndrome; ketogenic diet; leptin; ghrelin
1. Introduction
The classic ketogenic diet (cKD) is an isocaloric, high-fat, very low-carbohydrate and
normal-protein diet. It requires all foods and beverages to be carefully calculated and precisely
weighed on a gram scale in order to obtain a specific ratio between fats (gr) and carbohydrates (gr)
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plus proteins (gr), generally equal to 3:1 or 4:1 [1]. It has been used safely and effectively for decades
as a recognized treatment for drug-resistant epilepsy (DRE) [2–4], in GLUT1-Deficiency Syndrome
(GLUT1-DS) [5,6] and in pyruvate dehydrogenase complex deficiency (PDCD) [7,8]. While in DRE it
remains currently unclear how the cKD works despite a much better understanding of anticonvulsant
mechanisms [4], in the GLUT1-DS and PDCD it is the treatment of choice in order to switch brain
metabolism from glucose to ketone bodies (KBs) and leading to a powerful improvement in neurologic
symptoms. In fact, GLUT1-DS is a rare disease caused by mutations in the SLC2A1 gene that encodes the
glucose carrier protein type 1 (GLUT1), the main carrier of glucose across the blood-brain barrier, which
is characterized by early-onset seizures, developmental delay, and a complex movement disorder [9].
cKD has also been explored in other neurological and neurodegenerative diseases, such as Alzheimer’s,
Parkinson’s, amyotrophic lateral sclerosis, spinal cord injury, glycogenosis [10,11], and more recently
in metabolic syndrome and type 2 diabetes [12,13].
The cKD produces the highest ketogenic effect among the various ketogenic diets (KDs). It induces
a constant production of KBs, called ketosis, aimed at mimicking the starvation state while providing
adequate calories to support growth and energy needs in childhood and adult age, respectively [2,14].
KBs, such as acetone, acetoacetate andβ-hydroxybutyrate, are involved in several mechanisms [15].
Firstly, they have a “neuroketotherapeutic” effect [16], modulating the release of inhibitory
neurotransmitters, reducing neuronal excitation and seizure activity. They also have an antioxidant
effect, reducing the production of reactive oxygen species (ROS) and damage caused by them, and
increasing mitochondrial biogenesis and function [16]. In the GLUT1-DS and pyruvate dehydrogenase
complex deficiency, KBs are the main neuronal energy source [17]. Finally, KBs also appear to decrease
the pro-inflammatory cytokines that have an anti-inflammatory effect [15].
cKD may possibly also influence the modulation of multifunctional hormones such as ghrelin and
leptin [18–21]. These hormones are involved in food intake, glucose metabolism, neuronal activity and
also the maintenance of nutritional status [22,23]. Specifically, KBs may be implicated in the reduction
of food intake and consequent weight loss in adults [24] or in the potential adverse effect of growth
retardation in children during a long-term cKD [25–27].
Ghrelin is the only gastrointestinal peripheral peptide with orexigenic properties, whose circulating
plasma levels are increased by fasting and decreased by feeding [22]. Ghrelin’s concentration is also
inversely correlated with body weight and age [22,28]. It has been found to be an endogenous ligand
for the growth hormone secretagogue receptor (GHSR 1a), which can stimulate the release of growth
hormones (GH) from the anterior pituitary gland [29], inducing a broad spectrum of functions in
relation to food intake, adiposity and glucose metabolism [22]. In addition, it has anti-seizure effects,
which stimulate the release of protective neurotransmitters, which help to improve the survival and
proliferation of neurons [18,30]. Previous studies have investigated the short-term changes of ghrelin
during the cKD with contrasting results [18]. In fact, in children with DRE, decreased levels of ghrelin
were found after 3-months of cKD [19], whereas in adults the level increased [18,31].
Leptin, on the other hand, is an anorexigenic hormone, which is produced in small amounts at
a central level and widely released by a white adipose tissue into the circulatory system in order to
suppress hunger and, consequently, food intake [28]. Its blood concentration is directly proportional to
the amount of body fat mass, which is why its plasma levels increase in obese subjects [28]. The most
significant roles of leptin include the regulation of energy homeostasis, the neuroendocrine function
and metabolism [32], as it interacts with other hormonal mediators and regulators of energy status
and metabolism such as insulin, glucagon, insulin-like growth factors and growth hormones [23].
Some studies have hypothesized an increase in leptin in humans on the cKD, as shown also in rodents
placed on a cKD [33,34]. However, most human studies have shown that leptin decreases during KD,
probably due to the concomitant reduction of the adipose tissue [18,20,35].
Although ghrelin and leptin changes during cKD are of great interest due to their impact on
the nutritional and metabolic outcomes of cKD and their potential effects as therapeutic targets in
neurological diseases [30], to the best of our knowledge they have been analysed several times in DRE
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and GLUT1-DS [19–21], where the cKD must be followed for long term, but it is difficult to draw
substantial conclusions due to short follow-up examinations or incomplete data.
We therefore carried out a longitudinal study to investigate the effects of a 12-months cKD on
ghrelin and leptin concentrations in children, adolescents and adult patients affected by GLUT1-DS or
DRE. We also explored the relationship between the nutritional status, body composition and ghrelin
and leptin concentrations at the baseline as well as at 12 months.
2. Materials and Methods
2.1. Study Design
This was a 12-month, prospective, multi-centre study in patients with GLUT1-DS and DRE treated
with isocaloric cKD, according to the following criteria:
• age > five months;
• absence of absolute contraindications, such as carnitine deficiency, β-oxidation defects, pyruvate
carboxylase deficiency, and porphyria, as stated in the latest consensus [8];
• parents’ or caregivers’ compliance ensured by the physician who well explained to caregivers their
critical role in the administration of cKD to their children or parents, including the involvement of
time in the preparation of meals for the child who will require meals other than the rest of the
family, the cost of food, the avoidance of carbohydrates, additional supplementation and potential
side effects [8].
The main outcome measures were the changes in ghrelin and leptin from the baseline.
The assessment included neurological examinations; ghrelin and leptin dosage, glucose, insulin, and
lipid profile (triglycerides [TGs], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C],
and high-density lipoprotein cholesterol [HDL-C]); nutritional status evaluation by anthropometry
and abdominal body fat distribution by ultrasonography. In children and adolescents, we conducted
the assessment at the baseline and six and 12 months after cKD intervention, while in adults the
assessment was conducted at the baseline and after 12 months.
The study was approved by the ethical committee of the Fondazione IRCCS Policlinico San Matteo
of Pavia (reference number 20180083746) and complied with all tenets of the Helsinki declaration.
All the children’s and adolescents’ caregivers and adult patients provided written informed consent
before the beginning of the study.
2.2. Settings
Patients were recruited at the Department of Child Neurology and Psychiatry, Fondazione IRCCS
Istituto Neurologico C.Mondino in Pavia, and at the Pediatric Neurology Unit, “V. Buzzi” Hospital in
Milan, Italy from October 2010 to February 2018.
KD treatment was implemented at the Human Nutrition and Eating Disorders Research Centre in
Pavia, Italy.
Biochemical and anthropometric measurements were performed at the International Center for
the Assessment of Nutritional Status (ICANS) of the University of Milan, Italy.
2.3. Patients
We prospectively enrolled 30 patients: Twenty-five children and adolescents (15 females and
10 males, mean age 8 ± 4 years), of which 19 were affected by GLUT1-DS, and five adults (two females
and three males, mean age 34 ± 16 years), were all diagnosed with GLUT1-DS.
All the patients met the clinical criteria for the DRE and GLUT1-DS diagnosis:
• concerning GLUT1DS, all patients underwent a lumbar puncture in the fasting state (after 5–6 h of
fasting); a blood sample for glucose measurement was obtained immediately before the procedure
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to avoid stress-related hyperglycaemia [9]. A cerebrospinal fluid-to-blood glucose rate of <0.6 was
considered suspicious for GLUT1 DS. Subsequently, for a definitive confirmation, all the patients
were submitted to the SLC2 A1 mutation analysis;
• DRE was defined as “failure of adequate trials of two tolerated and appropriately chosen and
used antiepileptic drugs schedules to achieve sustained seizure freedom” according to the
Current International League Against Epilepsy (ILAE) Consensus [36]. It was diagnosed with the
Lennox Gastaut Syndrome (LGS), Electrical Status Epilepticus during Sleep (ESES), and epileptic
encephalopathy. All patients underwent magnetic resonance imaging (MRI) in order to classify
the cortical malformation. All patients were treated with specific pharmacotherapy. Seizure types
and epilepsy syndromes were classified according to the criteria proposed by the International
League Against Epilepsy (ILAE) [36].
2.4. Ketogenic Diet
A non-fasting dietary protocol with an at-home gradual increase of the ketogenic ratio was
implemented at the Human Nutrition Research Centre outpatient clinic according to a standardized
protocol [37].
At the baseline, we evaluated the usual caloric intake and food intolerances and preferences
for each patient using seven-day weighted food diaries analysed by a dietitian using the WinFood
version 3.0. The initial calorie prescription was based on age-related energy requirements considering
weight and height (both current and recent trends), and physical activity levels. The macronutrient
composition included a minimum of 0.8 g–1 g of protein from animal sources per kilogram of body
weight (e.g., eggs, milk, meat, poultry and fish).
All patients and caregivers received pre-diet counselling in order to ensure understanding
regarding the meal preparation, cooking strategy, importance of avoiding carbohydrates, additional
supplementation, and potential side effects.
All patients started a 1:1 cKD at home and gradually proceed to 2:1, 3:1 or 4:1 ketogenic ratio
in order to obtain blood values of beta-hydroxybutyrate >2.0 mml/L. All children’s and adolescents’
caregivers and adults were instructed to check capillary ketonemia and ketonuria on a daily basis
during the first month and then twice a week, and to report the values in a specific format. To measure
the dispersion of the ketonemia during cKD, for each patient we calculated the coefficient of variation
(CV) at the baseline and at 12 months as the ratio of the standard deviation to the mean of the reported
KBs. Ketonemia at the baseline was considered as the average of the daily KBs of the first two weeks
after the induction phase, while the final as the average of the last two weeks before the evaluation at
12 months.
24-h dietary recalls were collected during each follow-up examination to evaluate the compliance.
2.5. Main Outcome Measurements
2.5.1. Neurological Assessment
In accordance with the 2011 Italian consensus on KD therapy [38], neurologic evaluations and
electroencephalography (EEG) were performed after one, six and twelve months. The following
neurological symptoms were monitored: Paroxysmal dyskinesia, dysarthria, ataxia, spasticity dystonia,
muscle strength, as well as seizure types and frequency. Children’s and adolescents’ caregivers and
adult patients completed a daily record regarding alertness, activity and seizure occurrence.
2.5.2. Anthropometric Measurements
Anthropometric measurements were taken by the same trained dietician in accordance with
conventional criteria and measuring procedures [39].
Body weight (BW, kg) and body height (BH, cm) were measured to the nearest 100 g and 0.5 cm,
respectively. The body mass index (BMI) was calculated using the formula: BW (kg)/BH2 (m2).
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For children and adolescents, sex-specific BMI-for-age Z scores were calculated from the growth
charts of 2000 Centers for Disease Control and Prevention (CDC) [40]. In accordance with CDC
guidelines, a z-score of ≤−2 was considered as severely underweight, a score between −2 and −1
was considered underweight, between −1 and +1 was considered as normal weight, +1 and +2 was
considered overweight, and >+2 was considered as obese. For adults, the BMI was classified into four
categories: Underweight (BMI <18.5 kg/m2), normal weight (BMI 18.5 kg/m2–24.9 kg/m2), overweight
(BMI 25.0 kg/m2–29.9 kg/m2), and obese (BMI >30.0 kg/m2) [41].
Skinfold thickness was measured as proposed in a previous work [36] by a Holtain LTD caliper,
at the triceps, biceps, subscapular, and supra-iliac sites on the non-dominant side of the body.
All measurements were taken in triplicates for all sites, and the average of the three values was
calculated. The intra-observer variation for the skinfold measurement ranged between 2.5% and 2.9%.
The body density and fat mass (FM, kg) were calculated for children and for adolescents and adults by
the Brook method [42] and the Brozek Formula [43], and by the Durnin and Womersley method [44]
and the Siri formula [45], respectively. We calculated the fat mass index (FMI, kg/m2) in children and
adolescents by dividing FM by the squared height.
2.5.3. Abdominal Fat Distribution
Abdominal subcutaneous fat (SAT) and abdominal visceral fat (VAT) were measured on fasting
patients by the same operator using a Logiq 3 Pro Ultrasonography equipped with a 3.5 MHz
convex-array probe and with a 7.5 MHz linear probe (GE Healthcare, Milwaukee, WI, USA) following
a validated standardized protocol [46]. Specifically, SAT was measured as the distance between the
epidermis and the external face of the rectus abdominis muscle. VAT was measured as the distance
between the anterior wall of the aorta and the posterior surface of the rectus abdominis muscle
measured at the level of the xipho-umbilical line or linea alba. The within-day intra-operator coefficient
of variation for repeated measures of VAT and SAT in our laboratory is 0.8%.
2.5.4. Biochemical Parameters
Fasting blood samples were taken by venepuncture of the antecubital vein in either the sitting or
lying position, using vacuum tubes. After centrifugation (800× g 10 min at 5 ◦C), aliquots of samples
were stored at 80 ◦C until further analysis.
Ghrelin and leptin (pg/mL) were measured using an enzymatic immunoassay kit (R & D Systems;
Wiesbaden, Germany). Interassay precision (CV) was 3.3%, and 3.4%, respectively.
We used an autoanalyzer (Cobas Integra 400 plus, Roche Diagnostics, Mannheim) to determine
the serum glucose, TC, HDL-C, LDL-C, TG concentrations. Circulating insulin was measured in
duplicate by an autoanalyzer (Cobas e411 Hitachi, Roche Diagnostics). The homeostatic model
assessment-insulin resistance (HOMA-IR) was calculated as [fasting glucose (mg/dL) × fasting insulin
(mU/L)/405] [47].
High glucose was defined as glucose ≥100 mg/dL [48,49], high insulin as >23 uU/mL, and high
HOMA-IR as ≥3.16 for children or ≥2.5 for adults [47,50]. High TC was defined as ≥200 mg/dL, high
LDL-C as > 130 mg/dL, and high TG as >150, while low HDL as < 40 mg/dl for male and <50 mg/dL
for females [48,49].
Capillary ketonemia was measured with an in vitro diagnostic medical device for β-ketone
self-testing (GlucoMen LX PLUS, Menarini Diagnostics, test range 0.1 mmol/L–8.0 mmol/L). Ketonuria
was measured by a urine ketone stick test (Ketostix®, Bayer Diabetes, Berkshire, UK).”
2.6. Statistical Analysis
Continuous variables are presented as a mean± standard deviation. Leptin, insulin and HOMA-IR
were not normally distributed and were normalized using log-transformation. Similarly, ghrelin was
normalized using a square root transformation. An independent T-test was used to compare the
means of nutritional and biochemical variables between GLUT1-DS and DRE children. A one-way
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repeated measures ANOVA with Bonferroni’s test for comparison was run to determine if there were
differences in the variables of interest during the 12-month ketogenic dietary treatment. The Spearman
correlation was used to investigate the association of ghrelin and leptin concentrations and changes in
the nutritional status and body composition. All P-values were two-tailed, and p < 0.05 was considered
significant. Statistical analysis was performed using Stata 12.1 (Stata Corporation, College Station,
TX, USA).
3. Results
3.1. Pre-Intervention
Table 1 shows the characteristics of the patients at recruitment.
Table 1. Characteristics of the patients at recruitment.
Children and Adolescents Adults
Total GLUT1-DS DRE GLUT1-DS
(n = 25) (n = 19) (n = 6) (n = 5)
Mean Sd Mean Sd Mean sd p Value Mean sd
Age (years) 8 4 8 4 6 5 0.487 34 16
Nutritional status and body composition
Weight (kg) 27.5 20.4 28.2 19.0 25.4 24.5 0.573 63.5 9.1
Weight z-score −0.365 1.830 −0.340 1.868 0.454 1.888 0.761 - -
Height (cm) 120.0 29.1 122.5 27.8 111.9 34.3 0.751 168.4 6.9
Height z-score −0.603 1.177 −0.508 1.162 −0.825 1.294 0.424 - -
BMI (kg/m2) 16.5 4.3 16.5 4.3 16.4 4.9 0.745 22.6 4.9
BMI z-score −0.587 1.839 −0.423 1.353 −1.141 2.685 0.283 - -
Body fat (%) 20.8 7.0 21.0 6.2 34.4 11.6 0.773 27.2 12.8
FMI (kg/m2) 5.4 2.6 5.2 2.5 5.9 3.1 0.874 - -
SAT (cm) 0.8 0.7 0.8 0.8 0.7 0.7 0.561 5.4 6.9
VAT (cm) 2.9 1.6 2.7 1.7 3.5 1.1 0.307 9.65 11.2
Biochemical parameters
Serum glucose (mg/dL) 83 11 82 12 89 8 0.255 90 6
Log-Insulin (mU/L) 1.34 1.19 1.33 1.27 1.40 0.94 0.483 2.14 0.43
Log-HOMA-IR 0.24 1.25 0.27 1.35 0.64 0.11 0.473 0.63 0.45
TC (mg/dL) 170 37 174 39 154 20 0.255 201 14
HDL-C (mg/dL) 58 14 60 15 49 9 0.631 68 8
LDL-C (mg/dL) 99 33 100 36 98 16 0.269 121 12
TG (mg/dL) 61 18 60 17 66 25 0.743 57 14√
ghrelin (pg/mL) 19.74 6.44 17.98 5.91 25.3 4.930 0.895 17.84 2.83
Log-leptin (pg/mL) 8.58 1.16 8.60 1.20 8.49 1.12 0.796 9.26 1.30
KBs (mmol/L) 0.06 0.05 0.06 0.04 0.06 0.05 0.708 0.05 0.05
BMI = body mass index; FMI = fat mass index; SAT = abdominal subcutaneous fat; VAT= abdominal visceral
fat; HOMA-IR = homeostatic model assessment-insulin resistance; TC = total cholesterol, LDL-C = low-density
lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides; KBs = ketone bodies.
Among the children and adolescents, five patients were underweight (BMI z-score < −1,9)
according to the CDC BMI standards, one adult was underweight (BMI < 18.5), none were overweight
or obese. None of the children, adolescents or adults showed fasting glucose >100 mg/dL. Three
children and one adult had a high HOMA-IR index value (>2.5); three children and one adult had
both TC and LDL-C levels above the cut off; three children had low HDL-C levels, and none of them
showed triglyceride levels above the cut off. Both GLUT1-DS and DRE children and adolescents
reported ghrelin and leptin values in the normal range (395.19 ± 204.34 pg/mL; 6.82 ± 2.70 ng/mL;
respectively) [51,52]. No differences in the nutritional status, body composition and biochemical
parameters were found between GLUT1-DS and DRE children and adolescents.
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3.2. Intervention
Table 2 shows the macronutrient composition and ketogenic ratio of the cKD implemented by
the dietitian.
Table 2. Diet composition.
Children and Adolescents (n = 25) Adults
Total GLUT1-DS DRE GLUT1-DS
(n = 25) (n = 19) (n = 6) (n = 5)
Mean Sd Mean sd Mean sd p-Value Mean sd
Energy intake (kcal/day) 1373 518 1433 535 1132 401 0.315 1938 325
Energy intake/BW (kcal/kg) 61.5 21.3 59.5 17.5 69.2 34.2 0.662 31.6 9.5
Protein (g/day) 26.4 12.4 27.1 13.5 23.9 7.2 0.510 59.0 16.9
Protein/BW (g/kg) 1.2 0.5 1.1 0.3 1.5 0.9 0.348 1.0 0.3
Protein (%) 8 2 7 1 8 2 0.403 13 5
Fat (g/day) 131.3 51.0 137.4 51.8 107.0 43.6 0.316 177.6 43.5
Fat/BW (g/kg) 5.0 2.0 5.7 1.7 6.4 3.2 0.753 2.9 1.1
Fat (%) 86 5 86 3 85 8 0.697 82 8
SFA (g/day) 47.4 19.0 47.1 20.7 39.0 17.5 0.371 40.3 7.6
SFA/BW (g/kg) 2.0 0.7 1.7 0.8 1.7 0.8 0.407 0.6 0.2
SFA (%) 28 8 28 7 28 8 0.796 19 5
Carbohydrate (g/day) 21.6 12.6 22.4 11.7 18.6 17.1 0.641 20.1 8.7
Carbohydrate/BW (g/kg) 1.1 0.9 1.0 0.7 1.4 1.6 0.680 0.4 0.1
Carbohydrates (%) 7 4 7 3 7 6 0.873 4 2
Ketogenic ratio 2.9 0.8 2.9 0.7 2.8 1.1 1.000 2.5 0.9
BW = body weight (kg); SFA = saturated fatty acids.
There were no differences in the diet composition between GLUT1-DS and DRE children and
adolescents. All patients completed the 12-month protocol.
3.3. Post-Intervention
Children, adolescents and adults reached the therapeutic range of KBs (beta-hydroxybutyrate
>2.0 mmol/L) and tolerated the diet well. Table S1 shows changes of the diet composition at six and
12 months.
Neurological data on the effect of cKD have already been published in two papers by our research
group [53,54].
Table 3 shows changes at six and 12 months from the beginning of the cKD.
After 6-months of cKD, KBs increased significantly both in children and adolescents and in adults
(from 0.06 ± 0.05 to 2.78 ± 0.64 mmol/L, p-value = < 0.0001; from 0.05 ± 0.05 to 2.35 ± 1.36 mmol/L,
p-value = 0.022, respectively), and remained stable at 12-months, in line with the diet. At the end of the
induction phase, KBs were 2.99 ± 0.78 mmol/L with a CV equal to 19.3 ± 8.6%. At 12 months KBs were
2.89 ± 0.66 mmol/L with a CV equal to 20.4 ± 10.0% (p-value = 0.904).
Concerning children and adolescents, in the first six months, no significant differences were found
in the BMI z-score and the amount of body fat and its abdominal distribution. However, we found
a slight reduction of height z-score after 12 months of cKD (from −0.603 ± 1.178 to −0.953 ± 1.354,
p-value = <0.001). Regarding the biochemical parameters, although serum glucose did not change,
fasting insulin decreased after cKD, and HOMA-IR was significantly modified. Neither the lipid nor
leptin and ghrelin profiles changed significantly. None of these variables changed even at 12 months.
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Table 3. Time course of nutritional status, body composition and biochemical parameters during
12-month classical ketogenic diet (cKD).
Children and Adolescents (n = 25) Adults (n = 5)
Baseline 6 Months 12 Months Baseline 12 Months
Mean Sd Mean sd Mean sd p-Value Mean sd Mean sd p-Value
Nutritional status and body composition
Weight (kg) 27.5 20.4 29.4 20.1 29.0 18.5 0.124 63.5 9.1 62.4 5.0 0.469
Weight z-score −0.365 1.830 −0.605 1.320 −1.032 1.475 0.146 - - - - -
Height (cm) 120.0 29.1 124.0 30.8 125.2 28.4 <0.001 168.4 6.9 170.2 7.3 0.512
Height z-score −0.603 1.177 −0.505 1.014 −0.953 1.354 <0.001 - - - - -
BMI (kg/m2) 16.5 4.3 17.1 3.5 16.7 3.3 0.694 22.6 4.9 21.7 3.4 0.276
BMI z-score −0.587 1.839 −0.228 1.337 −0.609 1.295 0.917 - - - - -
Body fat (%) 20.8 7.0 21.7 6.1 21.2 5.8 0.712 27.2 12.8 23.0 10.1 0.349
FMI (kg/m2) 5.4 2.6 6.01 2.6 6.35 1.9 0.207 - - - - -
SAT (cm) 0.8 0.7 0.7 0.5 0.8 0.4 0.875 5.4 6.9 1.5 1.2 0.492
VAT (cm) 2.9 1.6 3.0 1.2 2.6 1.2 0.921 9.65 11.2 3.7 0.9 0.183
Biochemical parameters
Serum glucose
(mg/dL) 83 11 78 8 79 12 0.094 90 6 96 10 0.354
Log-Insulin (mU/L) 1.34 1.19 0.89 0.83 1.10 0.93 <0.001 2.14 0.43 1.66 0.37 <0.001
Log-HOMA-IR 0.24 1.25 −0.78 0.89 −0.54 1.01 <0.001 0.63 0.45 0.21 0.40 0.034
TC (mg/dL) 170 37 178 39 174 40 0.688 201 14 188 34 0.348
HDL (mg/dL) 58 14 61 16 62 19 0.207 68 8 66 11 0.135
LDL (mg/dL) 99 33 110 32 102 32 0.546 121 12 123 31 0.963
TG (mg/dL) 61 18 70 33 67 29 0.294 57 14 57 25 0.990√
ghrelin (pg/mL) 19.74 6.44 18.77 6.23 18.90 6.17 0.693 17.84 2.83 15.06 3.43 0.102
Log-leptin (pg/mL) 8.58 1.16 8.57 1.02 8.68 0.90 0.808 9.26 1.30 9.13 1.01 0.898
KBs (mmol/L) 0.06 0.05 2.78 0.64 2.45 1.77 <0.001 0.05 0.05 2.65 0.82 0.022
BMI = body mass index; SAT = abdominal subcutaneous fat; VAT = abdominal visceral fat; HOMA-IR =
homeostatic model assessment-insulin resistance; TC = total cholesterol, LDL-C = low-density lipoprotein cholesterol;
HDL-C = high-density lipoprotein cholesterol; TG = triglycerides; KBs = ketone bodies.
Similarly, in adults after 12-month cKD, no significant changes were observed in the body
composition and abdominal fat amount (SAT and VAT). Maintenance of serum glucose occurred, while
insulin and HOMA-IR changed significantly. Neither ghrelin nor leptin and nor TC/LDL/HDL/TG
changed significantly.
3.4. Associations between Nutritional Status, Body Composition, Ghrelin and Leptin
Tables 4 and 5 show the associations between the nutritional status and body composition with
concentrations and changes in ghrelin and leptin pre-intervention and post-intervention, both in
children and adults, respectively.
At pre-intervention, in children and adolescents, the ghrelin concentration correlated negatively
with the age and BMI z-score (ρ = −0.5180, p = 0.0080; ρ = −0.4493, p = 0.0410; respectively) and as
expected, the leptin concentration correlated positively with the weight z-score, BMI z-score and body
fat amount (ρ = 0.4707, p = 0.0234; ρ = 0.6351, p = 0.0020; ρ = −0.5896, p = 0.0101; respectively). Insulin
correlated negatively with ghrelin concentration (ρ = 0.5134, p = 0.0210).
At post-intervention, no correlations were found between ∆ghrelin concentration and changes in
the nutritional status and body composition variables, whereas the ∆leptin concentration correlated
positively with variations in the weight z-score and body fat (ρ = 0.4534, p = 0.0341; ρ = 0.5901,
p = 0.0135; respectively).
In adults, no correlations were found between the nutritional status, body composition, leptin,
and ghrelin either in pre-intervention or in post intervention.
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Table 4. Associations between nutritional status, body composition, ghrelin and leptin at the baseline and 12-months in children and adolescents.
Pre-Intervention Post-Intervention
Age Weightz-Score
Height
z-Score
BMI
z-Score Body fat
√
ghrelin LOG-Leptin Log-Insulin ∆Weightz-Score
∆Height
z-Score
∆BMI
z-Score
∆Body
fat ∆
√
ghrelin ∆Log-Leptin ∆Log-Insulin
Age ρ 1.0000
p-value
Weight
z-score
ρ 0.2170 1.0000 ∆Weight
z-score
ρ 1.0000
p-value 0.3199 p-value
Height
z-score
ρ 0.3113 0.6856 1.0000 ∆Height
z-score
ρ 0.1261 1.0000
p-value 0.1816 0.0012 p-value 0.6069
BMI z-score
ρ 0.5076 0.9059 0.5237 1.0000 ∆BMI
z-score
ρ 0.8784 −0.4246 1.0000
p-value 0.0188 0.0000 0.0178 p-value 0.0000 0.0620
Body fat ρ 0.5412 0.6870 0.3470 0.8021 1.0000 ∆Body fat ρ 0.7368 −0.3167 0.7761 1.0000
p-value 0.0210 0.0020 0.1872 0.0001 p-value 0.0012 0.2334 0.0001
√
ghrelin ρ −0.5180 −0.3533 −0.2886 −0.4493 −0.3435 1.0000 ∆√ghrelin ρ −0.1988 0.0019 −0.1848 −0.1247 1.0000
p-value 0.0080 0.0982 0.2172 0.0410 0.1642 p-value 0.3751 0.9963 0.4225 0.6245
Log-Lept ρ 0.1766 0.4707 0.2977 0.6351 0.5896 −0.1724 1.0000 ∆Log-Leptin ρ 0.4534 0.3963 0.0364 0.5901 0.0142 1.0000
p-value 0.3984 0.0234 0.2024 0.0020 0.0101 0.4100 p-value 0.0341 0.0930 0.8789 0.0135 0.9475
Log-Insulin ρ 0.6031 0.5012 0.0023 0.6152 0.4032 −0.5134 0.4025 1.0000 ∆Log-Insulin ρ 0.0704 0.1182 −0.0105 −0.2754 0.0725 0.0051 1.0000
p-value 0.0049 0.0288 0.9931 0.0095 0.1368 0.0210 0.0792 p-value 0.7821 0.6751 0.9702 0.3215 0.7695 0.9852
BMI = Body mass index. Age (years); Body fat (%);
√
ghrelin (pg/mL); Log-leptin (pg/mL); Log-Insulin (mU/L).
Table 5. Associations between nutritional status, body composition, ghrelin and leptin at the baseline and 12-months in adults.
Pre-Intervention Post-Intervention
Age Weightz-Score
Height
z-Score
BMI
z-Score
Body
Fat
√
ghrelin Log-Leptin Log-Insulin ∆Weightz-Score
∆Height
z-Score
∆BMI
z-Score
∆Body
Fat ∆
√
ghrelin ∆Log-Leptin ∆Log-Insulin
Age ρ 1.0000
p-value
Weight
z-score
ρ −0.1010 1.0000 ∆Weight
z-score
ρ 1.0000
p-value 0.8990 p-value
Height
z-score
ρ −0.1900 −0.7740 1.0000 ∆Height
z-score
ρ 0.7370 1.0000
p-value 0.8100 0.2260 p-value 0.2630
BMI z-score
ρ −0.0370 0.9710 −0.9010 1.0000 ∆BMI
z-score
ρ 0.9654 0.5390 1.0000
p-value 0.9630 0.0290 0.0990 p-value 0.0350 0.4610
Body fat ρ 0.4510 0.7830 −0.9330 0.8670 1.0000 ∆Body fat ρ 0.5960 0.8340 0.3940 1.0000
p-value 0.5490 0.2170 0.0670 0.1330 p-value 0.4040 0.1660 0.6060
√
ghrelin ρ 0.3770 −0.9150 0.5660 −0.8500 −0.4850 1.0000 ∆√ghrelin ρ −0.4310 −0.9250 −0.1820 −0.8220 1.0000
p-value 0.5310 0.0850 0.4340 0.1500 0.5150 p-value 0.5690 0.0750 0.8180 0.1780
Log-Lept ρ −0.2360 0.7650 −0.9050 0.8770 0.7110 −0.6840 1.0000 ∆Log-Leptin ρ 0.5160 0.1090 0.6440 −0.3450 0.1090 1.0000
p-value 0.7020 0.2350 0.0950 0.1230 0.2890 0.2020 p-value 0.4840 0.8910 0.3560 0.6550 0.8610
Log-Insulin ρ −0.891 0.3470 −0.2300 0.3630 −0.0840 −0.5910 0.6220 1.0000 ∆Log-Insulin ρ 0.8850 0.3490 0.9621 0.3330 0.1600 0.2770 1.0000
p-value 0.0420 0.6530 0.7700 0.6370 0.9160 0.2940 0.2630 p-value 0.1150 0.6510 0.0380 0.6670 0.7970 0.6520
BMI = Body mass index. Age (years); Body fat (%);
√
ghrelin (pg/mL); Log-leptin (pg/mL); Log-Insulin (mU/L).
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4. Discussion
The main aim of our longitudinal study was to investigate the effects of a 12-month cKD on ghrelin
and leptin concentrations in children, adolescents and adult patients affected by GLUT1-DS or DRE.
To the best of our knowledge, this is the first that it has been demonstrated that in the long-term, cKD
did not change ghrelin and leptin concentrations independently of age and the neurological condition
for which the cKD was prescribed.
These results are in contrast with those obtained by Marchiò et al. [19]. These authors studied only
children affected by DRE and found a significant reduction in both ghrelin and des-acyl ghrelin plasma
levels during a cKD. However, their study was short-term with a follow-up of only three months, and
the differences in ghrelin concentrations are probably due to an initial metabolic adaptation to the high
fat content of the cKD. Other authors, such as Sumithran [55] and Nymo et al. [56], examined changes
in all appetite-regulating peripheral hormones and found a significant increase in ghrelin associated
with a high change in body composition after a KD. However, they examined the effects of a very
low energy diet (VLED) on overweight and obese adults with an only 8–10-week follow-up. VLEDs
are also called “starvation diets” due to their extremely low daily amount of energy, equal to about
800 kcal/day, one third of the average energy requirement for a man (2500 kcal) and half for a woman
(2000 kcal). VLEDs are usually undertaken by overweight and obese patients for rapid weight loss and,
due to the strong reduction in food calories that VLED requires, cannot be followed for long periods.
Compared to cKD, VLEDs provide a higher protein content (1.5 g/kg/day), in order to accelerate fat
oxidation and KB production and better control hunger and satiety.
Regarding leptin, these results confirm our previous ones in a smaller sample (n = 10) and with a
shorter follow-up (3-months) [34] but are in contrast with the results of Lambrechts et al. [20]. These
authors found a leptin decrease after a 12-month KD in patients affected by DRE aged between one and
40 years, following various KDs, such as cKD and medium chain triglyceride (MCT) KD which uses
a fat supplement consisting only of MCT fats that produce ketones more easily than the long-chain
ones used in the cKD. However, their KD was different from the cKD, because they gradually added
five-gram steps to the diet with a maximum of 20 g/day of carbohydrates when adequate ketosis was
not reached or to prevent weight loss. Rauchenzauner et al. [21] also reported decreased leptin levels
in children affected by GLUT-1 DS and treated with a cKD for at least six months: this change was not
dependent on weight loss.
The different types of KDs examined, the various study-designs and the different ages and diseases
of the examined patients, could explain these contrasting results.
Our study showed stable ghrelin and leptin concentrations, probably due to the isocaloric cKD,
which permitted a stable KB production without impairing the nutritional status. Indeed, the BMI
did not change significantly, and the amount and distribution of body fat also remained stable,
corroborating our previously published data on the short-term effects of cKD on the nutritional status
and body composition in children affected by GLUT1-DS [28]. We found, as expected [23,32], that
the leptin concentration changes were positively associated with the weight gain and the increase in
body fat amount (ρ = −0.4534, p = 0.0344; ρ = 0.5901, p = 0.0135; respectively). Some authors have
hypothesized a downregulated concentration in ghrelin and, in contrast, an increase in leptin levels
during KDs ad libitum due to the increase in dietary fat intake and, consequently, a higher body fat
mass [18,33]. However, the strict and constant evaluation of both the caloric and fatty acid intakes,
probably led to the maintenance of the nutritional status, lipid profile and both ghrelin and leptin
levels in the 12-month cKD. These data, taken together, suggest that, weight loss, probably including
both fat mass and fat free mass loss, as occurred during the VLED, rather than KBs, affects the ghrelin
and leptin concentration, acting on hungry and satiety control. During a normocaloric cKD, KBs do
not seem to directly regulate body weight and body composition.
After 12 months of cKD, in our sample of children and adolescents, we found a statistically
significant reduction in the height z-score, with a magnitude of variation of very low clinical impact
(−0.19 ± 0.15 height z-score). A decline in height [27] or weight and height [57–61] with the KD has
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been previously described in epileptic patients on the diet for more than six months; and the percentage
of affected patients varies between 6% and 30% in recent long-term studies [62–64].
Data on factors that may affect the growth of children treated with the KD (e.g., ketosis or nutrient
adequacy) remain scarce and contrasting [26,65]. However, a reduction in both ghrelin and insulin,
both of which are hormones stimulating GH concentration, has been hypothesized [29,66]. Our study
does not suggest the potential role of ghrelin on the delay of growth, because we did not find either
a significant change in ghrelin over the 12 months (p = 0.693), or an association with the ghrelin
and height z-score changes (ρ = 0.0019, p = 0.9963). As for insulin, although we found a significant
difference between the baseline and 12 months (p < 0.001), insulin was not significantly associated with
the height z-score changes (ρ = −0.1182, p = 0.6751). However, we cannot rule out that insulin changes
may have had an effect during cKD and led to growth failure. This is because from a metabolic point of
view not only is the fasting concentration of insulin relevant but also the after-meal concentration. The
chronic very low amount of carbohydrates of the cKD could significantly impair insulin secretion after
a meal. Further studies on the effects of the ketogenic diet on insulin secretion are needed to clarify
this issue.
Regarding the biochemical parameters, children, adolescents and adults reported unchanged
fasting glucose, while there was a drop in the fasting insulin and a relative improvement in HOMA-IR,
as previously demonstrated [34]. The three children and one adult (13%) with high TC and LDL at
the baseline, reported a rise (+25%) in both levels, while triglycerides remained in the normal range.
In the other patients, the lipid profile did not change, despite the daily high-fat dietary consumption,
in contrast with a previous study [67] that found a substantial increase in TC, HDL, LDL and TG at six
months. Our results agree with a previous study that found no significant changes in TC or LDL-C
in 10 prepubertal children affected by GLUT1-DS after 10 years of a cKD and did not identify any
cardiovascular risks [6].
One of the strengths of the study is the quality of data collected: All the biochemical measurements
and dosages were collected in the same centre, thus guaranteeing less variability. It is also the first
time that ghrelin, leptin, insulin and nutritional status parameters have been measured all together
and both in DRE and, above all, in GLUT1-DS. Finally, our study involved what we believe to be the
longest follow-up ever reported in the literature. However, a number of potential limitations need to
be addressed. A control group was not included in the study, since this is difficult to achieve especially
because the GLUT1-DS management guidelines require the use of KD from the first day of diagnosis [5].
The sample size is also globally small, especially in adults, and thus more studies are needed.
5. Conclusions
The present study is, to the best of our knowledge, the first to investigate the effects of a 12-month
cKD on ghrelin and leptin concentrations in children, adolescents and adults affected by GLUT1-DS or
DRE. We found no significant changes and associations between the ghrelin and leptin and nutritional
status changes, suggesting that these appetite-regulating peripheral hormones are not downregulated
by chronic ketosis or by a very high fat diet. Our results contribute to the growing literature on
changes during cKD of these two peripheral hormones implicated in several metabolic outcomes, and
thus to a better understanding of the long-term effects of a cKD and how it could be implemented in
other diseases.
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